The widening net loss combined with heavy dilution from the $5.0M private placement and $1.5M warrant exercises is a clear negative for a $6M market cap stock. The $8.3M cash runway provides some buffer, but without revenue or a near-term catalyst beyond the IND submission timeline, the stock remains highly speculative and vulnerable to further dilution. Monitor for any update on the IND submission timeline for EB-003, as that is the primary value driver.
Price Chart
Executive Summary
Enveric Biosciences reported a Q2 2026 net loss of $3.0M ($0.76 per share), wider than the $2.5M loss in Q2 2025, but the per-share loss narrowed dramatically from $11.65 due to a massively increased share count from recent dilutive financings. The company raised $6.5M in gross proceeds during the quarter ($5.0M private placement + $1.5M warrant exercises) and ended with $8.3M cash, extending its runway toward a planned IND submission for lead candidate EB-003. Preclinical data for EB-003 continues to support a non-hallucinogenic profile, but the company remains pre-revenue with no near-term catalyst beyond the IND timeline, and the persistent dilution is a material overhang for a $6M market cap stock.
Key Financial Metrics
Key Facts
- Net loss of $3.0M for Q2 2026 vs $2.5M in Q2 2025, a 20% wider loss.
- Basic and diluted loss per share of $0.76 vs $11.65 in the prior-year quarter — the dramatic narrowing reflects massive share dilution from recent financings.
- Cash-on-hand of $8.3M as of June 30, 2026.
- Raised $5.0M in upfront gross proceeds from a private placement and an additional $1.5M from warrant exercises during the quarter.
- Preclinical data for EB-003 continues to show a non-hallucinogenic profile in GloSensor and BRET assays, and genotoxicity studies have been initiated.
- Received a Notice of Allowance from the USPTO for the EVM401 Series and secured U.S. Patent No. 12,605,361 for the EVM301 Series.
Financial Impact
Net loss widened by $0.5M year-over-year to $3.0M. Dilution is severe — per-share loss dropped from $11.65 to $0.76 despite a larger absolute loss, implying a massive increase in share count.
Risk Factors
- Persistent dilution from recent and potential future financings to fund operations.
- Pre-revenue status with no guarantee of successful IND submission or clinical trial outcomes for EB-003.
- Widening net loss indicates cash burn is accelerating, potentially requiring additional capital raises.
- Stock is highly speculative with a $6M market cap — any negative news could lead to significant downside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-038385 |
| Document: form8-k.htm | 0001493152-26-038385 |
| Document: 0001493152-26-038385-index-headers.html | 0001493152-26-038385 |
| Document: 0001493152-26-038385-index.html | 0001493152-26-038385 |
| Document: 0001493152-26-038385.txt | 0001493152-26-038385 |
| 8-K Data (Synthetic) | 0001493152-26-038385 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 8-K | $1.48 $1.46 | ▲ +1.35% | ▼ −0.63% | $1.42 (+4.05%) |
Jun 9, 2026 20w ago | 8-K | $1.62 $1.43 | ▲ +11.73% | ▲ +15.35% | $1.42 (+12.35%) |
Jun 9, 2026 20w ago | 424B5 | $1.62 $1.43 | ▲ +11.73% | ▲ +15.35% | $1.42 (+12.35%) |
May 29, 2026 21w ago | 8-K | $2.26 $1.38 | ▲ +38.94% | ▲ +37.64% | $1.42 (+37.17%) |
May 15, 2026 23w ago | 8-K | $2.25 $1.48 | ▼ −34.22% | ▼ −36.34% | $1.42 (−36.89%) |
Apr 23, 2026 26w ago | S-3 | $5.04 $2.22 | ▲ +55.95% | ▲ +59.98% | $1.42 (+71.83%) |
Apr 14, 2026 28w ago | DEFA14A | $2.03 $2.52 | ▲ +24.14% | ▲ +18.09% | $1.42 (−30.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers